Navigation Links
Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance
Date:3/12/2010

ee and twelve months ended December 31, 2009, respectively. Revenues totaled $44,000 and $0.3 million for the three- and twelve-month periods ended December 31, 2008, respectively. The revenues earned during 2009 resulted from the recognition of a portion of the upfront, non-refundable license fee and reimbursement of third-party development costs under our license agreement with Bayer. The $35.0 million upfront license fee has been recognized on a straight-line basis over a period of approximately 13 months, which was the original period in which we expected to complete all of our obligations under the license agreement with Bayer. In December 2009, we revised our estimate of this period extending it to 26 months as a result of design modifications to our ongoing RDEA119 clinical trials. The unamortized balance of the license fee as of the date of the change in estimate will be recognized over the revised timeline. The revenue earned in fiscal 2008 resulted from the research services we provided under our master services agreement with Valeant, which has since terminated by its terms.

The net loss applicable to common stockholders for the three and twelve months ended December 31, 2009 was $6.3 million and $30.9 million, or $0.34 per share and $1.70 per share, respectively, compared to a net loss applicable to common stockholders for the same periods in 2008 of $12.7 million and $5
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014 The steady decline ... spreading to previously rep-friendly specialties, according to the ... marketing consulting firm ZS Associates.      ... U.S. pharmaceutical sales teams. The report examines how ... with the pharmaceutical sales reps who visit their ...
(Date:7/22/2014)... -- BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: ... appointed Charles J. (Chuck) Bramlage and Dr. ... Board.  Mr. Bramlage is a veteran ... and other commercial functions.  He is currently the Chief ... company that was recently acquired by AstraZeneca and is ...
(Date:7/22/2014)... , July 22, 2014  UL (Underwriters ... that the U.S. Food and Drug Administration (FDA) ... consensus standards for medical devices incorporating lithium or ... - Standard for Household and Commercial Batteries, and ... Consensus standards are standards recognized ...
Breaking Medicine Technology:Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 2Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 3Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 4Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 5BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 2BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 3BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 4BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 5BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 6BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 7Two UL Battery Safety Standards Are now FDA Recognized Consensus Standards for Medical Devices 2
... China Medicine Corporation (OTC Bulletin Board: CHME ... of Western pharmaceuticals, traditional Chinese medicines ("TCM"), and other ... announced that it has filed with the United States ... Form 8-K to disclose that its previously issued financial ...
... THOUSAND OAKS, Calif., March 23, 2011 Amgen ... data that showed postmenopausal women with osteoporosis had ... (denosumab) treatment than during alendronate treatment, an oral ... Adherence to treatment, which includes both compliance ...
Cached Medicine Technology:China Medicine Corporation Files Extension for Fiscal 2010 Form 10-K Filing 2China Medicine Corporation Files Extension for Fiscal 2010 Form 10-K Filing 3Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 2Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 3Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 4Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 5Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 6Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 7Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 8Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 9Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 10Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 11
(Date:7/22/2014)... Roanoke, VA (PRWEB) July 22, 2014 ... as a young child. While most kids outgrow ... Tonelson did not. He is among the three million ... can range from mild to severe. Throughout his youth, ... attending in-school speech sessions and visits with private speech-and-language ...
(Date:7/22/2014)... 2014 BESLER Consulting, a leading ... for hospitals, is pleased to offer a complimentary ... to assist hospitals with analyzing their 2015 QualityNet ... on July 21 allow hospitals to validate their ... However, the data contained in these reports can ...
(Date:7/22/2014)... 2014 Kirby Lester, LLC, the leading ... includes streamlined functionality to perform a trackable double-count for ... Since a double-count of controlled medications is required, the ... quickly perform a second count of any tablet or ... of the second count up to 10 years. This ...
(Date:7/22/2014)... Hill, South Carolina (PRWEB) July 22, 2014 ... weight loss solution managed to lose 20 pounds. Unfortunately, the ... shaky and nauseated for the duration of her time using ... ‘manic’. One woman experienced heart flutters and insomnia as a ... woman experienced a heart attack at the age of 37 ...
(Date:7/22/2014)... 22, 2014 Ronald S. Weaver, ... Inglewood, Calif., today announced a heart transplant patient with ... Counterpulsation (EECP) therapy at Global Cardio Care Centers and ... , The patient, a 55-year-old Hispanic male, also ... Life Program, a nutrition and exercise lifestyle program in ...
Breaking Medicine News(10 mins):Health News:New Steps in the “Ballet of Speech” Create Life-Changing Possibilities for People Who Stutter 2Health News:New Steps in the “Ballet of Speech” Create Life-Changing Possibilities for People Who Stutter 3Health News:New Steps in the “Ballet of Speech” Create Life-Changing Possibilities for People Who Stutter 4Health News:Complimentary Re-admissions Analytics Tool Available From BESLER Consulting 2Health News:Kirby Lester KL1Plus Pharmacy Automation Perfect for Double-Counting & Tracking Prescriptions from Any Pharmacy Robot 2Health News:SlimPlate System Urge Women to Shun Controversial Weight Loss Pills for Healthier Methods Like Portion Control 2Health News:Ronald S. Weaver, MD, Owner of Global Cardio Care Centers, Announces EECP Treatment Success for Cardiomyopathy Patient Who Needed Heart Transplant 2Health News:Ronald S. Weaver, MD, Owner of Global Cardio Care Centers, Announces EECP Treatment Success for Cardiomyopathy Patient Who Needed Heart Transplant 3
... ... professionals are turning to BurrellesLuce for valuable advice on making optimal use of Twitter and ... ... public relations practice, many PR professionals are turning to BurrellesLuce for valuable advice ...
... LINO LAKES, Minn., Aug. 26 Despite ... construction firms have been recognized by Minnesota Laborers-Employers Cooperation and ... 2008. , , Begun in 2007, the ... performance and proactive approach of Skilled Construction Union Laborers and ...
... , , WASHINGTON, Aug. ... who was a champion for vulnerable people throughout his life and a ... the midst of America,s great discussion of health care reform, Kennedy was ... We hope that Congress will honor his memory with the completion of ...
... arsenic from the body, according to a new study that ... the potentially toxic substance. The study found that some people ... the diet. Others store arsenic in their bodies, where it ... application of new methods for studying arsenic, is scheduled for ...
... , , WILMINGTON, ... comparative effectiveness study performed by HealthCore, Inc. in its August ... better clinical outcomes with oral controllers than inhaled corticosteroids. , ... requested the comparative effectiveness study to help ensure that its ...
... , JERICHO, N.Y., Aug. 26 Optimum ... New York metropolitan area businesses, today announced that Medical ... in Long Island, has selected Optimum Lightpath as its ... Optimum Lightpath,s 100% fiber Ethernet connection, Medical Arts Radiology ...
Cached Medicine News:Health News:PR Professionals Making Good Use of Social Media With Help From Twitter Webinars Run by BurrellesLuce 2Health News:PR Professionals Making Good Use of Social Media With Help From Twitter Webinars Run by BurrellesLuce 3Health News:Twenty-Two Regional Construction Firms Recognized for Their Commitment to Worker Safety 2Health News:Comparative Effectiveness Research Study in Mayo Clinic Proceedings Demonstrated Asthma Patients Had Better Overall Results with Oral Controllers than Inhaled Products 2Health News:Comparative Effectiveness Research Study in Mayo Clinic Proceedings Demonstrated Asthma Patients Had Better Overall Results with Oral Controllers than Inhaled Products 3Health News:Comparative Effectiveness Research Study in Mayo Clinic Proceedings Demonstrated Asthma Patients Had Better Overall Results with Oral Controllers than Inhaled Products 4Health News:Medical Arts Radiology Chooses Optimum Lightpath to Speed Anytime, Anywhere Access to Patient Data and Communications 2Health News:Medical Arts Radiology Chooses Optimum Lightpath to Speed Anytime, Anywhere Access to Patient Data and Communications 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: